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We present our views on current and past epidemiological contributions to our understanding of neuroim-
mune mechanisms for neurodevelopmental disorders, such as schizophrenia. We also discuss future direc-
tions for epidemiological studies and ways in which newer cohorts are well positioned to address questions
that were previously not feasible to explore.Epidemiologic studies have made power-
ful contributions to the understanding and
prevention of neurodevelopmental disor-
ders. Some of these contributions are
famous, for example, the work on neural
tube defects, which ultimately demon-
strated that maternal periconceptual
folate supplements reduce the risk among
their offspring (Susser et al., 2008). Others
are less widely known, such as the recent
advances that have been made for
schizophrenia, where epidemiologic find-
ings are being replicated and suggesting
pathways for neuroscience research.
These findings include—but are not
limited to—the high risk of schizophrenia
among minority groups in Western Eu-
rope, among offspring of older fathers,
and among offspring of mothers exposed
to famine in early gestation (March and
Susser, 2006).
Moreover, the scope of epidemiologic
research on neurodevelopmental disor-
ders is growing exponentially. Many large
cohorts have now been followed prospec-
tively from in utero up to young adulthood
(Susser et al., 2000). Another set of very
large cohorts (100,000 or more) have
recently been established or are in the
process of being established, with in-
depth measures of prenatal experience,
archived biological specimens, and fol-
low-up of neurodevelopmental outcomes.
National registries have been established
in many countries—most notably Scandi-
navian countries—which allow us to study
millionsof people, via linkageof population
registries, birth registries (and sometimes
archived prenatal biological specimens),and treatment registries.Finally, the impor-
tanceof collaboration across large cohorts
and across national registries is increas-
ingly recognized and much facilitated by
developments in informatics. These and
other developments have brought us into
a newera for epidemiologic studiesof neu-
rodevelopment.
But much of the groundwork has
already been laid. To illustrate the evolv-
ing contribution of epidemiological re-
search toward advancing our under-
standing of neuroimmune interactions,
we use the example of prenatal infection
and schizophrenia, for which the potential
importance of neuroimmune processes
has become quite evident.
Epidemiological Evidence Linking
Prenatal Infection and
Schizophrenia
The first epidemiological studies linking
prenatal infection to schizophrenia were
ecologic studies. Although there are
some conflicting findings, many of these
studies found that mothers who were
pregnant during an influenza epidemic
had offspring with an increased risk of
schizophrenia (Brown, 2006). Neverthe-
less, ecological studies are limited by
the inability to determine whether infec-
tion actually occurred, given that infection
is assumed based on events that occur
for an entire population. In fact, it is
possible that offspring of mothers who
did not manifest influenza symptoms
may have been at greatest risk, as these
mothers may have had the most vigorous
immune response to influenza exposure.Neuron 6Subsequently stronger epidemiological
evidence linking prenatal infection to
schizophrenia was derived from longitu-
dinal cohort studies that prospectively
collected obstetric information (including
maternal sera during pregnancy in some
studies) and identified those who devel-
oped schizophrenia or other psychotic
disorders. Generally these studies com-
pared the individuals who developed
schizophrenia with a sample of those
who did not, a strategy known as a
‘‘nested case-control’’ design (Susser
et al., 2006). Although there has not
been complete consistency among these
studies, a series of infections during
pregnancy (ascertained from medical
chart reviews and/or serological analyses
of archived maternal sera) have been
associated with risk of schizophrenia
in offspring, including influenza, rubella,
maternal upper respiratory infections,
genital reproductive infections, and
herpes simplex virus-type 2 (HSV-2)
(Brown, 2006). Immunologic evidence of
prior exposure to toxoplasma gondii has
also been associated with schizophrenia
(Brown, 2006).
A puzzle presented by these data is the
wide range of infections for which asso-
ciations have been reported. Since none
of these findings are yet definitive, one
explanation is that many are false posi-
tives, and we have yet to determine the
one or few that are truly related to schizo-
phrenia. Until now, almost all studies with
biological measures of prenatal infection
have shared certain limitations, such as
small sample sizes.4, October 15, 2009 ª2009 Elsevier Inc. 25
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tious exposures exert effects by a
common mechanism, for example, by
invoking an immune response. Indeed,
evidence from animal studies suggests
that most viral infections do not appear
to cross the placenta; therefore, the tera-
togenic influences might be more related
to maternal, fetal, and/or placental re-
sponses to infection (Patterson, 2009).
Given this possibility, two nested case-
control studies examined the relationship
between fetal exposure to elevations in
a panel of maternal proinflammatory cyto-
kines during pregnancy and risk for
schizophrenia in offspring (Brown et al.,
2004b; Buka et al., 2001). The first study
found an association between maternal
tumor necrosis factor-alpha (TNF-a)
levels at birth with increased risk of
schizophrenia in offspring, whereas the
second study found an association
between fetal exposure to the maternal
chemokine, interleukin-8 (IL-8) during the
second/third trimesters and risk for
schizophrenia in offspring (Brown et al.,
2004b; Buka et al., 2001). Although both
of these cytokines are associated with
inflammation, it remains unclear whether
exposure to specific cytokines during
specific periods of gestation portends
greater risk for subsequent psychopa-
thology in offspring. Again, these studies
were faced with limitations in sample
size and measurement which can be
overcome in the current era.
In a similar vein, there have been
inconsistent findings concerning which
period(s) during pregnancy incur the
most risk for subsequent difficulties in
offspring. Many of the ecologic studies
examining exposure to an influenza
epidemic during pregnancy have found
that the second trimester may be particu-
larly important in portending increased
risk for schizophrenia (Brown, 2006).
However, the first study using serologi-
cally documented influenza infection
from archived maternal sera found that
exposure in early gestation was most
important and found no impact of third-
trimester influenza exposure (Brown
et al., 2004a). Further, a second study
with prenatal sera, which had samples
only from birth (corresponding to infection
in the third trimester), found that third-
trimester influenza exposure was related
to increased risk of schizophrenia among26 Neuron 64, October 15, 2009 ª2009 Elseoffspring (Ellman et al., 2009). Studies of
other factors have found evidence for
effects in both early (e.g., maternal starva-
tion, maternal bereavement, maternal
rubella) and late (e.g., hypoxic events)
gestation (Cannon et al., 2002).
Some of these apparently discrepant
findings on timing of exposure may not
hold up over time. Nonetheless, it is
possible that there are sensitive periods
where the fetus is especially vulnerable
to exposure to infection and immune
responses associated with infection and
that these sensitive periods differ depend-
ing on the infectious agent—or even the
particular strain of an infectious agent
(Ellman et al., 2009)—and the subsequent
neurodevelopmental sequelae.
It is also possible that fetal exposure to
infection only incurs risk in individuals
who have a preexisting vulnerability asso-
ciated with schizophrenia. Specifically,
one study found that fetal exposure to
influenza B led to decreases in cognitive
performance among 7-year-olds who
later developed schizophrenia in adult-
hood, but not among control children
who had no evidence of psychiatric
morbidity in adulthood (Ellman et al.,
2009). Another study found that the influ-
ence of fetal exposure to maternal pyelo-
nephritis (urinary and bladder infections)
on risk for schizophrenia was only evident
in those who had a family history of
a psychotic disorder (Clarke et al., 2009).
Although these findings are suggestive
of gene-environment interactions, no
study has directly tested whether specific
genetic polymorphismsmake certain indi-
viduals more vulnerable to the effects of
infection and immune-related conditions.
Neuroimmune Mechanisms in the
Current Era
Neuroimmune mechanisms are now
being considered as potential risk factors
for a wide range of neuropsychiatric
outcomes (e.g., Patterson, 2009). With
the vastly greater scope and precision of
epidemiologic investigations, and the
advancing technology for measuring
genetic and biological factors, the oppor-
tunities for epidemiologic studies of these
processes are enormous.
First, we can now examine the effects
of specific exposures—such as prenatal
starvation, increased paternal age, and
specific strains of infection—on neuroim-vier Inc.mune processes and potential mecha-
nisms for these effects such as muta-
genesis and epigenetic modifications.
Second, the role of timing of the prenatal
exposure can be investigated with much
more precision. Third, we can examine
the possibility that some individuals are
genetically susceptible to these expo-
sures (Ellman et al., 2009), for example,
carry genetic polymorphisms that are
associated with increased inflammatory
responses or dysregulation in immune
functioning. Fourth, we can study genetic
and other maternal characteristics which
potentially contribute to immune func-
tioning of mothers during pregnancy and
subsequent risk for psychopathology in
offspring. Body mass index, exercise,
sleep, and health-risk behaviors (e.g.,
substance use and abuse) have all been
linked to alterations in immune func-
tioning and susceptibility to infection and
disease (e.g., Irwin et al., 2008; Seger-
strom and Miller, 2004). Fifth, we can
begin to study fetal sex by immune
interactions in the pathogenesis of neuro-
developmental disorders, which has been
relatively understudied (Ellman et al.,
2008). Finally, the newer epidemiological
studies have the potential to map out
the relationship between early immune-
related exposures and important interme-
diate phenotypes throughout develop-
ment, such as cognitive functioning, brain
development, and social functioning,
which ultimately could lead to targets for
early intervention. It is only in the current
era that we have the power and tech-
nology to arrive at definitive answers to
these questions.
Conclusion
Intriguing epidemiologic evidence on
prenatal infection and schizophrenia
exemplify the plausibility of neuroimmune
mechanisms for mental disorders but also
the limitations of available evidence. In
the current era, we are already shifting to
larger epidemiologic studies with more
precise measures of multiple prenatal
exposures and indicators of neuroim-
mune status. These studies can examine
more definitively whether prenatal infec-
tions (or other exposures) are related
to schizophrenia. Lastly, although we
have often used schizophrenia as an
example, it is imperative for epidemiolog-
ical investigations to determine whether
Neuron
NeuroViewimmune-related risk factors portend in-
creased risk for disorders other than
schizophrenia or phenotypes that are
shared between disorders. Current epide-
miological investigations are well posi-
tioned to tackle many of these questions,
which could lead to results that will
greatly inform primary prevention and
early intervention strategies for mental
disorders.
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